Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 00002-3270
Summary:
NDC 00002-3270 is marketed as Simvastatin Tablets 20 mg, initially approved in 1987. It remains widely prescribed for lowering LDL cholesterol and preventing cardiovascular events. The market for simvastatin has faced declining volumes due to generic competition and evolving lipid management guidelines. Current pricing trends and future projections indicate continued price erosion influenced by market saturation, payer negotiations, and increased generic penetration.
Market Overview
Product Details:
- Active ingredient: Simvastatin
- Strength: 20 mg
- Formulation: Tablets
- Initial approval: 1987
- Generic entry: 1990s, leading to significant price reductions
Market Size & Usage:
- Estimated U.S. prescriptions: approximately 25 million in 2022 (IQVIA)
- Market share dominance: Simvastatin historically captured 40-50% of statin prescriptions before generic competition
- Declining trend: Prescriptions have steadily decreased 5-8% annually from 2018 to 2022, partly due to increased focus on alternative lipid lowering agents such as PCSK9 inhibitors and ezetimibe
Competitive Landscape:
- Multiple generics available since late 1990s
- Leading brands: Zocor (Johnson & Johnson) - original; Teva, Sandoz, Mylan, and others produce generic versions
- Patent status: expired, no recent patent protections
Price Trends & Projections
Historical Pricing:
- Brand Zocor (pre-generic): Average wholesale acquisition cost (WAC) around $450–$500 per month (2000s)
- Generic simvastatin (post-1999): WAC declined to approximately $10–$20 per month in recent years for 30-day supplies
- Pharmacy benefit manager (PBM) net prices further lower, often below $10 per month
| Current Price Range (2023): |
Pricing Metric |
Approximate Figure |
Notes |
| WAC |
$10–$20 per month |
Widely available generics |
| Average selling price |
$5–$10 per month |
Negotiated discounts and rebates reduce effective prices |
| Patient copay |
$0–$10 |
Under assistance programs or insurance discounts |
Forecast Trends:
- Short-term (1–3 years):
Prices will remain stable or decline slightly as generic competition intensifies. Market consolidation and payer pressure will sustain low prices. Expect WAC to hover around $5–$15 per month.
- Medium-term (3–5 years):
The market for statins could contract further as clinicians shift toward newer agents, especially in patients with statin intolerance or familial hypercholesterolemia. Price erosion may plateau, but cost-saving trends will persist.
- Long-term (5+ years):
Price stabilization is likely, with potential slight increases if shortages or supply chain issues arise. If patent litigations or regulatory changes occur (e.g., biosimilar-like pathways for generics), prices could fluctuate upward.
Factors Influencing Future Market and Pricing
-
Regulatory Changes:
A new biosimilar pathway for small molecules could influence pricing dynamics. Currently, no biosimilars are in progress for simvastatin.
-
Market Competition:
The presence of multiple generics constrains pricing power of manufacturers. Any reduction in generic supply could stabilize or increase prices.
-
Clinical Guidelines and Prescribing Patterns:
The 2018 ACC/AHA guidelines emphasize LDL reduction, still endorsing statins as first-line therapy. However, the rise of alternative lipid agents could reduce volume.
-
Insurance & Rebate Dynamics:
Payer negotiations and rebates heavily influence the net price; these are confidential and can vary widely.
Strategic Considerations
- Manufacturers aiming for profitability should focus on operational efficiencies as generic prices decline.
- Payers will continue to favor low-cost generics, exerting downward pressure.
- Innovation in lipid-lowering therapy could further erode the market share of older statins.
Key Takeaways
- NDC 00002-3270 (simvastatin 20 mg) faces an increasingly mature, price-competitive market.
- Prices are expected to remain low, with monthly WAC ranging from $5 to $15 over the next five years.
- Long-term dynamics depend on shifts toward alternative therapies and regulatory developments.
- Prescribing volume is declining due to market saturation and changing clinical practices.
- Competitive pressures will sustain low prices, limiting profit margins for manufacturers.
FAQs
1. What is the primary driver for price decline in generic simvastatin?
Market saturation and direct competition among multiple generic manufacturers drive prices downward.
2. How does the prescription volume of simvastatin influence pricing?
Declining prescription volumes reduce overall market demand, exerting further downward pressure on prices.
3. Are there any new formulations or patents protecting simvastatin?
No, patent protections have expired, and new formulations are not under development; the drug remains a generic.
4. How might regulatory changes impact simvastatin’s market?
Introduction of biosimilar-like pathways could increase generic competition or lead to a price stabilization or increase if supply constraints develop.
5. Will newer lipid-lowering agents replace simvastatin?
Possibly in some patient populations; PCSK9 inhibitors and other therapies are more expensive but offer benefits for specific cases.
References
[1] IQVIA. 2022 Medicine Use and Spending Data.
[2] FDA. Summary of Simvastatin Drug Approvals.
[3] Medscape. Lipid-Lowering Agents Market Analysis.
[4] Medicare and Commercial Payer Data Reports.
